Sort
21,453 grants matching “tuberculosis”
Population Based Molecular epidemiology of Tuberculosis
$761,225Philip C Hopewell · University Of California, San Francisco · R01 · FY2009 · AI
A low-cost instrument for nucleic acid isolation.
$761,218Christopher Gerard Cooney · Akonni Biosystems, Inc. · R44 · FY2015 · GM
Siderophore Inhibitors for Tuberculosis that Block Mycobactin Biosynthesis
$761,214Courtney C Aldrich · University Of Minnesota · R01 · FY2020 · AI
Integrative Omics of HepB Vaccine Response in Co-Infection with Parasites
$761,155Elias K Haddad · Drexel University · U19 · FY2021 · AI
A Cytomegalovirus-based Vaccine Targeting the Pre-erythrocytic Stage of Malaria
$760,985Klaus J Frueh · Oregon Health & Science University · R01 · FY2019 · AI
Project 1 Immunometabolic Determinants of Susceptibility
$760,647Christopher M Sassetti · Univ Of Massachusetts Med Sch Worcester · P01 · FY2025 · AI
Immunometabolic regulations of pulmonary TB pathogenesis by adiposetissue
$760,645Jyothi Falguni Nagajyothi · Hackensack University Medical Center · R01 · FY2021 · AI
Hearing impairment in HIV-infected and HIV/TB-coinfected individuals in Tanzania
$760,630Jay C Buckey · Dartmouth College · R01 · FY2010 · DC
Admixture Mapping of Sarcoidosis Genes in African American
$760,606Benjamin A. Rybicki · Henry Ford Health System · R01 · FY2010 · HL
A New Approach to an Old Problem: Redesigning Latent Tuberculosis Screening and Treatment
$760,514Sara Tartof · Kaiser Foundation Research Institute · R01 · FY2024 · AI
TUBERCULOSIS ELIMINATION AND LABORATORY
$760,370Frank J Wilson · Arkansas State Department Of Health · U52 · FY2007 · PS
SOC Core
$760,028Aleksandar Milosavljevic · Baylor College Of Medicine · U54 · FY2014 · DA
Epidemiology of coronary artery disease among people with HIV in rural sub-Saharan Africa
$759,919Mark J Siedner · Massachusetts General Hospital · R01 · FY2021 · HL
Longitudinal Studies of HIV-Associated Lung Infections and Complications
$759,809Kristina Anne Crothers · University Of Washington · R01 · FY2009 · HL
Molecular mechanisms of inherent drug resistance in non-tuberculous mycobacteria
$759,743Eric Joseph Rubin · Harvard School Of Public Health · R01 · FY2023 · AI
Novel delivery platform and antigen design for an effective COVID-19 vaccine
$759,584Suresh K Mittal · Purdue University · R01 · FY2025 · AI
Optimization of Atypical Antimycobacterial Carbapenem Antibiotics
$759,402John D Buynak · Southern Methodist University · R01 · FY2023 · AI
Post-TB epigenetic scars' impact on long-term inflammation, immunity and mortality
$759,188Andrew R Dinardo · Baylor College Of Medicine · R01 · FY2023 · AI
Development of novel penems for drug-resistant tuberculosis
$759,045Craig A Townsend · Johns Hopkins University · R01 · FY2021 · AI
Point of care detection of fluroquinolone, bedaquiline and linezolid resistant Mycobacterium tuberculosis for rapid treatment decisions.
$758,976David Alland · Rutgers Biomedical And Health Sciences · R01 · FY2025 · AI
Chemical biology studies of MmpL3 inhibition and resistance in mycobacteria
$758,959Robert B Abramovitch · Michigan State University · R01 · FY2023 · AI
Using Lipids for Vaccination
$758,772Luc Teyton · Scripps Research Institute, The · U01 · FY2009 · AI
Durban International Clinical Trials Unit
$758,768Umesh G Lalloo · Ukzn Innovation · UM1 · FY2012 · AI
Therapeutic vaccination to augment stringent response-specific T-cell immunity to MTB persisters
$758,696Petros C Karakousis · Johns Hopkins University · R01 · FY2021 · AI
Characterization of Signaling Pathways involved in Cell Death and Survival
$758,637Srinivasa M. Srinivasula · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA